Adherence to glatiramer acetate treatment for multiple sclerosis: The Brazilian experience

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 41-46

  de Oliveira, Tatiana de Melo Gomes ^a   Fiore, Ana Patricia Peres ^b   Fragoso, Yára Dadalti ^b  

^a TEVA Pharmaceutical ^*  (Brazil)

^b UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

Author keywords

Adherence; Glatiramer acetate; Multiple sclerosis

Indexed keywords

EID: 79955509341     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S2255     Document Type: Article

References (16)

1. Devonshire V., Lapierre Y, MacDonell R, et al. 2006. The Global Adherence Project-a multicentre observational study on adherence to diseasemodifying therapies in patients suffering from relapsing-remitting multiple sclerosis [abstract]. Presented at: 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 27-30, 2006; Madrid, Spain.
2. Fiore A. PP, Fragoso YD. 2005. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Arq Neuropsiquiatr, 63:738-40.
3. Ford C. C, Johnson RP, Lisak RP, et al, and the Copaxone Study Group. 2006. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler, 12:309-20.
4. Fragoso Y. D, Fiore APP. 2005. Description and characteristics of 81 patients attending the Reference Center for Multiple Sclerosis of the coastal region of the state of Sao Paulo-Brazil. Arq Neuropsiquiatr, 63:741-4.
5. Fraser C., Hadjimichael O, Vollmer T. 2001. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs, 33:231-9.
6. Frohman E., Brannon K, Alexander S, et al. 2004. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler, 10:302-7.
7. Hadjimichael O., Vollmer TL. 1999. Adherence to injection therapy in MS: Patient survey. Neurology, 52(Suppl 2):A549.
8. Rio J., Porcel J, Tellez N, et al. 2005. Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Mult Scler, 11:306-9.
9. O'Rourke KE, Hutchinson M. 2005. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler, 11:46-50.
10. Parker D., Beach B. 2006. Improving adherence and compliance: 90 days high risk compliance call questions. Personal communication 2006, Global Seminar on Nurse and Patient Education; 30th-31st January, Lucerne, Switzerland; and Annual Meeting May 30th-June 2nd, 2007 Washington DC, Consortium of Multiple Sclerosis Centers-Poster S56.
11. Rovaris M., Comi G, Rocca M, et al, and European/Canadian Glatiramer Acetate Study Group. 2007. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI monitored trial. Mult Scler, 13:502-8.
12. Thouvenot E., Hillaire-Buys D, Bos-Thompson MA, et al. 2007. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Mult Scler, 13:941-4.
13. Tremlett H. L, Orger J. 2003. Stopping and switching of the ß-interferons prescribed for MS. Neurology, 61:551-4.
14. Wolinsky J.S. 1995. Copolymer 1: a most reasonable alternative therapy for early relapsing remitting multiple sclerosis with mild disability. Neurology, 45:1245-7.
15. World Health Organization. 2003. Adherence to long term therapies: evidence for action. Geneva: World Health Organization. Chapter I, section I.
16. Young V. 2002. Differential mechanisms of action of interferon-YYand glatiramer acetate in MS. Neurology, 59:802-8.